Novo Nordisk A/S ADR (NVO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-1995 | 12-1994 | 12-1993 | 12-1992 | 12-1991 | |
| Cash Flows From Operating Activities | |||||
| Net Income | 0 | N/A | 1,425,941 | 1,275,817 | 928,423 |
| Depreciation Amortization | 0 | N/A | 796,507 | 695,336 | 591,134 |
| Other Working Capital | 0 | N/A | -517,295 | -655,307 | -549,686 |
| Other Operating Activity | 456,500 | 0 | 202,847 | 15,419 | 201,666 |
| Operating Cash Flow | $456,500 | $N/A | $1,908,000 | $1,331,265 | $1,171,537 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | 0 | N/A | N/A | -2,147,148 | -1,556,290 |
| Other Investing Activity | -182,060 | 0 | -2,036,809 | 2,147,148 | -1,474,730 |
| Investing Cash Flow | $-182,060 | $N/A | $-2,036,809 | $0 | $-3,031,020 |
| Cash Flows From Financing Activities | |||||
| Dividend Paid | 0 | N/A | -148,877 | -146,405 | -125,705 |
| Other Financing Activity | -242,400 | 0 | 481,676 | 536,781 | 1,903,398 |
| Financing Cash Flow | $-242,400 | $N/A | $332,799 | $390,376 | $1,777,693 |
| Exchange Rate Effect | 0 | N/A | 2,715 | 0 | -4,347 |
| Beginning Cash Position | 0 | N/A | 586,921 | 0 | 639,573 |
| End Cash Position | 0 | N/A | 793,626 | 0 | 553,436 |
| Net Cash Flow | $12,200 | $N/A | $206,705 | $0 | $-86,137 |
| Free Cash Flow | |||||
| Operating Cash Flow | 456,500 | N/A | 1,908,000 | 1,331,265 | 1,171,537 |
| Free Cash Flow | 456,500 | 0 | 1,908,000 | 1,331,265 | 1,171,537 |